Phathom Pharmaceuticals
Price & Volume
Stats
See more52W Range | $7.61-$18.31 |
Market Cap | $854.1M |
Shares Short | 10M |
Financials
See moreRevenue (12 Mos) | $204.8M |
Revenue Growth (YoY) | 104.4% |
Gross Profit (12 Mos) | $174M |
Diluted EPS | -$2.09 |
News
See moreYahoo Finance • 2 months ago
Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight
Yahoo Finance • 3 months ago
Phathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target
Yahoo Finance • 3 months ago
Noteworthy Thursday Option Activity: INTU, AMPX, PHAT
Yahoo Finance • 4 months ago
Phathom Pharmaceuticals Pivots to GI Focus, Targets 2H 2026 Profitability, CEO Says at Guggenheim Summit
About
CEO | Mr. Steven L. Basta M.B.A. |
Address | 100 Campus Drive, Florham Park, NJ, United States, 07932 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 371 |